Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01884272 · ClinicalTrials.gov registry record · Phase 1
NSAID Drug Interaction Study
A Phase 1 study of Gout, sponsored by Ardea Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT01884272 is a Phase 1 study of Gout that has completed, run by Ardea Biosciences. The registered enrollment target is 24 participants, below the 8,888-participant average among 34 other Gout trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01884272, a Phase 1 study of Gout, has completed, sponsored by Ardea Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a drug-drug interaction study in healthy volunteers to evaluate the potential pharmacokinetic (PK) effects of non-steroidal anti-inflammatory drugs on lesinurad and leinurad on the non-steroidal anti-inflammatory drugs.
Conditions Studied
Interventions
- DRUG lesinurad 400 mg
- DRUG naproxen 250 mg
- DRUG indomethacin 25 mg
Study Locations (1)
Michigan
- - Kalamazoo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-06 |
| Est. Completion | 2013-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01884272
The ClinicalTrials.gov registry entry for NCT01884272 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 8,888-participant average among 34 other Gout trials with a reported enrollment target (100% lower). The listed sponsor is Ardea Biosciences, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gout appearing as the primary indexed condition, and to 3 interventions - of which lesinurad 400 mg is the first listed.
NCT01884272 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT01884272 about?
NCT01884272 is a clinical study titled "NSAID Drug Interaction Study". This is a drug-drug interaction study in healthy volunteers to evaluate the potential pharmacokinetic (PK) effects of non-steroidal anti-inflammatory drugs on lesinurad and leinurad on the non-steroidal anti-inflammatory drugs.
What is the current status of trial NCT01884272?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2013-06. Estimated completion is 2013-10.
What conditions does trial NCT01884272 study?
This clinical trial studies the following conditions: Gout.
What interventions are being tested in trial NCT01884272?
The interventions under investigation include: lesinurad 400 mg (DRUG), naproxen 250 mg (DRUG), indomethacin 25 mg (DRUG).
Who is sponsoring clinical trial NCT01884272?
This trial is sponsored by Ardea Biosciences, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01884272 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gout
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Pharmacodynamics of SEL-037 (Pegsiticase) in Subjects With Elevated Blood Uric Acid Levels
COMPLETED · Phase 1
-
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients with Hyperuricemia
COMPLETED · Phase 1
-
Mild, Moderate and Severe Renal Impairment Study
COMPLETED · Phase 1
-
The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults.
COMPLETED · Phase 1
-
Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.